Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 6:57 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 313–336 of 1,207 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Low Dose Drug A Clear all

Conditions: Open-angle Glaucoma, Ocular Hypertension
Interventions: High Dose Drug Device, Low Dose Drug Device, Placebo Device, bimatoprost 0.03%; Drug
Lead sponsor: Vistakon Pharmaceuticals; Industry
Eligibility: 21 Years and older
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2009
U.S. locations: 5
States / cities: Miami, Florida • Philadelphia, Pennsylvania • Mt. Pleasant, South Carolina + 2 more

Conditions: Common Cold
Interventions: Acetaminophen 650mg+Dextromethorphan 20mg+Phenylephrine 10mg, Acetaminophen 325mg+Dextromethorphan 10mg+Phenylephrine 5mg; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 21 Years to 45 Years · Male only
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Ulcerative Colitis, Crohn's Disease
Interventions: Vedolizumab; Drug
Lead sponsor: Takeda; Industry
Eligibility: 2 Years to 17 Years
Enrollment: 89 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 27
States / cities: Los Angeles, California • Orange, California • San Francisco, California + 22 more

Conditions: COVID-19, Acute Respiratory Distress Syndrome, Severe Acute Respiratory Syndrome (SARS), Coronavirus Infections
Interventions: Naltrexone, Ketamine, Placebo; Drug · Other
Lead sponsor: Corewell Health East; Other
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Royal Oak, Michigan

Conditions: Healthy Volunteers
Interventions: Danavorexton, Danavorexton Placebo, Propofol, Sevoflurane; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: HIV Infections, Pregnancy
Interventions: Ritonavir, Saquinavir, Lamivudine, Zidovudine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2003
U.S. locations: 14
States / cities: Los Angeles, California • Denver, Colorado • Washington D.C., District of Columbia + 9 more

Conditions: Metastatic Castration-resistant Prostatic Neoplasms
Interventions: Pasritamig, Placebo, Best Supportive Care (BSC), JNJ-87189401; Biological · Other · Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 1,203 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 55
States / cities: La Jolla, California • Los Angeles, California • San Francisco, California + 43 more

Conditions: Type 2 Diabetes Mellitus
Interventions: efpeglenatide (SAR439977), placebo; Drug
Lead sponsor: Hanmi Pharmaceutical Company Limited; Industry
Eligibility: 18 Years and older
Enrollment: 406 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 32
States / cities: Birmingham, Alabama • Glendale, Arizona • Canoga Park, California + 26 more

Conditions: Breast Cancer
Interventions: trastuzumab (Herceptin®); Drug
Lead sponsor: University of Michigan Rogel Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Hookworm Infection, Hookworm Disease
Interventions: Na-GST-1/Alhydrogel®, CpG 10104; Biological
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 18 Years to 50 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: COVID-19, Acute Kidney Injury, Sepsis
Interventions: SBI-101; Biological
Lead sponsor: Sentien Biotechnologies, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 2
States / cities: Albuquerque, New Mexico • Charleston, South Carolina

Conditions: Hypogonadism
Interventions: Testopel 75mg Drug Implant, Testopel 100mg Drug Implant, Testopel 200mg Drug Implant; Drug
Lead sponsor: University of Miami; Other
Eligibility: 18 Years to 75 Years · Male only
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Brain Tumor, Recurrent
Interventions: Photofrin (porfimer sodium) & photodynamic therapy.; Drug
Lead sponsor: Harry T Whelan, MD; Other
Eligibility: 6 Months to 18 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 1
States / cities: Wauwatosa, Wisconsin

Conditions: Body Weight, Contraceptive Usage
Interventions: All participants (Aviane), Portia, Aviane; Drug
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 18 Years to 35 Years · Female only
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Myelodysplastic Syndromes
Interventions: FDA-approved drug or combination of drugs, FLAG induction, 7 + 3 induction, Low-dose cytarabine, Supportive care alone, Computational biology simulations software; Drug · Other · Device
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 99 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Patent Ductus Arteriosus After Premature Birth
Interventions: Ibuprofen; Drug
Lead sponsor: IWK Health Centre; Other
Eligibility: Up to 72 Hours
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 3
States / cities: Orange, California • San Diego, California • Oklahoma City, Oklahoma

Conditions: Open Angle Glaucoma, Ocular Hypertension
Interventions: AR-17043 Ophthalmic Solution, PG043 Ophthalmic Solution, Latanoprost 0.005% Ophthalmic Solution, Netarsudil 0.02% Ophthalmic Solution, Netarsudil 0.02%/Latanoprost 0.005% Ophthalmic Solution, AR-17043 Vehicle; Drug
Lead sponsor: Alcon Research; Industry
Eligibility: 18 Years and older
Enrollment: 646 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 25
States / cities: Dothan, Alabama • Phoenix, Arizona • Garden Grove, California + 20 more

Conditions: Dermatitis, Atopic
Interventions: Placebo, SCD-044_Dose 1, SCD-044_Dose 2, SCD-044_Dose 3; Drug
Lead sponsor: Sun Pharmaceutical Industries Limited; Industry
Eligibility: 18 Years and older
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 34
States / cities: Phoenix, Arizona • Yuma, Arizona • Encino, California + 23 more

Conditions: Stable Chronic Heart Failure
Interventions: CD-NP, Placebo; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 21 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Obesity & Overweight, Cardiometabolic Health Indicators
Interventions: GLP-1 dose reduction, non-GLP weight loss medication, Maintenance of GLP-1 dose, Resistance exercise regimen, Lifestyle/nutrition counseling; Drug · Behavioral
Lead sponsor: Jing Luo; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Epithelial Carcinoma, Solid Tumor
Interventions: SYN125, SYN004; Biological
Lead sponsor: Synermore Biologics Co., Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 4
States / cities: Fairway, Kansas • Brownstown, Michigan • St Louis, Missouri + 1 more

Conditions: Lymphoma
Interventions: filgrastim, chemotherapy, in vitro-treated peripheral blood stem cell transplantation, peripheral blood stem cell transplantation, radiation therapy; Biological · Drug · Procedure + 1 more
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 18 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Diabetic Foot Ulcers
Interventions: ATG002 (study drug); Drug
Lead sponsor: CoMentis; Industry
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 13
States / cities: Homewood, Alabama • Phoenix, Arizona • Tucson, Arizona + 10 more

Conditions: Pain, Intractable, Breakthrough Pain, Chronic Pain
Interventions: Bupivacaine, Opioid; Drug
Lead sponsor: University Hospitals Cleveland Medical Center; Other
Eligibility: 31 Years to 90 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Cleveland, Ohio

Search by objective public record fields.

Safety and Efficacy of a Drug Delivery System in Glaucoma

To Investigate the Gastrointestinal Behaviour of Two Triple Combination Products in Healthy Male Volunteers

Vedolizumab IV in Pediatric Participants With Ulcerative Colitis (UC) or Crohn's Disease (CD)

Study of Immunomodulation Using Naltrexone and Ketamine for COVID-19

A Study of Danavorexton in Anesthetized Adults

Fortovase (Saquinavir) Given With Low-Dose Ritonavir, Zidovudine, and Lamivudine to HIV-Positive Pregnant Women During and After Pregnancy and to Their Newborns

A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)

Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Diet and Exercise

Use of Trastuzumab to Induce Increased ER Expression in ER-negative/Low, Her-2/Neu Positive Breast Cancer

Safety and Immunogenicity Study of Na-GST-1 With or Without CpG

A Study of Cell Therapy in COVID-19 Subjects With Acute Kidney Injury Who Are Receiving Renal Replacement Therapy

Testopel ® vs. Generic Testosterone Pellets.

Photodynamic Therapy (PDT) for Recurrent Pediatric Brain Tumors

Oral Contraceptives and Body Mass Index

iCare 2: Personalized Genomic Mutation Informed Treatment of Patients With Myelodysplastic Syndromes

Selective Early Medical Treatment of Patent Ductus Arteriosus in Extremely Low Gestational Age Infants: A Pilot RCT

Next Generation Rocklatan

To Assess the Efficacy and Safety of SCD-044 in the Treatment of Moderate to Severe Atopic Dermatitis

CD-NP in Subjects With Stable Chronic Heart Failure

Comparing Different Medication Regimens to Maintaining Weight Loss Among Adults With Obesity Using GLP-1s

A Study to Find the MTD of SYN125 in People With Solid Tumors and the MTD of SYN125 With a Fixed Dose of SYN004 in People in Patients With Epithelial Cancers With EGFR Expressions

Peripheral Stem Cell Transplantation in Treating Patients With Relapsed Low- or Intermediate-Grade Non-Hodgkin's Lymphoma

Safety and Preliminary Efficacy Study of Nicotine Gel to Treat Diabetic Foot Ulcers

Patient Controlled Intrathecal Analgesia With Bupivacaine for Chronic Low Back Pain